Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavorixafor (Primary)
  • Indications WHIM syndrome
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Acronyms 4WHIM
  • Sponsors X4 Pharmaceuticals

Most Recent Events

  • 01 May 2025 According to a X4 Pharmaceuticals media release, published abstract has been accepted for poster presentation at the upcoming meeting of the Clinical Immunology Society (CIS).
  • 24 Jan 2025 According to a X4 Pharmaceuticals media release, Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome, has been validated for review and is now under evaluation with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).Decision on MAA expected in 1H 2026.
  • 24 Jan 2025 According to a X4 Pharmaceuticals media release, EMA's decision on MAA is expected in 1H 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top